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Comparative Effectiveness Research (CER)
and Evidence-Based Medicine (EBM) is at
the heart of many transformative changes in
health care, driven in part by the Affordable
Care Act (ACA). Robert W. Dubois, MD,
PhD, Chief Science Officer at the National
Pharmaceutical Council, offered a compelling
and succinct overview of CER and EBM at a
Forum this past spring.
The National Pharmaceutical Council (NPC)
is a health policy research organization
focused on the advancement of good evidence
and science, and fostering medical innovation
within the United States. Dr. Dubois oversees
NPC’s research on policies related to CER
and health outcomes. Throughout his career,
Dr. Dubois’ primary interest has centered
on defining “what works” in health care and
finding ways for that evidence to inform health
care decision making. He is a recognized
expert in defining best practices, disease
management and appropriateness of care.
Dr. Dubois began his presentation by
explaining that CER is not exactly new,
but that it is related to EBM and decision

making; in other words, it is important that
it is used to examine and improve clinical
practice. He refers to Eddy’s model of
thought process that describes evidence,
scientific judgments and value judgments,
and how these influence decisions. 1
Dubois described EBM as a general concept of
using evidence to apply to a clinical decision,
whereas CER is a more patient-focused
strategy that compares alternative approaches
to management. Dubois provides an easy
approach to the thought process around CER
by using these questions: What works when?
For whom? And Under what circumstances?
Adding to this, he outlines characteristics
that are critical to CER and decision making:
delivery of the right care, to the right patient, at
the right time, in the most appropriate setting.
He states that we have to make this easy to do
and embedded in how we make health choices.
Although there is overlap between CER,
EBM and Health Technology Assessment
(HTA), Dubois identified differences: CER
is primarily a research activity to answer
certain questions; EBM is focused on

the application; and HTA is centered on
assessment and cost-effectiveness.
Dubois discussed two major motivators
illustrating the need for CER. First, patients
face many alternative therapeutic options to
manage their conditions, and comparative
evidence is often not available. Second, the
complex and chronic conditions characteristic of
the baby boomer population demand different
and effective health strategies, especially as we
face concerns about rising health care costs.
Dubois went on to discuss the relationship
between CER and medications. He described
the challenges of population vs. individual
results. For example, efficacy data on certain
medications may not apply to individuals.
Posing the question, “Will access to
medications be constrained?” Dubois states
that this could vary in different states. This
is an example of how difficult it can be to
translate CER into policy choices. 
For more information on the National
Pharmaceutical Council visit:
http://www.npcnow.org/

Grandon Workshop
A special additional session of the Population Health Forum for Grandon Society Members
April 17, 2013
In this workshop, Dr. Dubois continued to discuss CER through a stimulating discussion of heterogeneity and the importance of
finding a balance between CER results at the population level and when that may be applied appropriately to the individual.
Dubois identified key factors to be taken into account when considering variation in individual treatment response as: likelihood
of response to similar treatments; clinical consequences of delaying optimal treatment; underlying patient diversity; and patient
preferences. These factors influence and affect the higher risk and clinical impact of heterogeneity. Dubois used the example of
treatments for depression and multiple sclerosis to show how difficult it is to provide a population-based framework for treatment.
Individual differences and patient preferences are significant factors in treatment strategies.
The audience had the opportunity to ask a number of questions, and the interactive session also addressed issues of payments for
tests, companion diagnostics, and value-based purchasing. Dr. Dubois concluded by discussing some of the new payment changes to
providers, where they will be accountable for both the economics of care, and quality performance.

